Menu Search
Equities

LSL Pharma Group Inc

LPGIF:PKC

LSL Pharma Group Inc

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company. The Company is specialized in the development, manufacturing and commercialization of sterile ophthalmic pharmaceuticals, as well as natural health products in solid dosage forms. It specializes in the manufacturing and marketing of natural health products (NHPs). The Company manufactures a range of NHPs in liquid, powder and capsule form, sold under its own brand or under private labels. Its manufacturing activities include blistering, encapsulation, sachet and jar filling. The Company's subsidiaries include Steri-Med Pharma Inc., LSL Laboratory Inc. and Groupe Immobilier LSL inc.

  • Revenue in CAD (TTM)12.17m
  • Net income in CAD-4.62m
  • Incorporated2010
  • Employees--
  • Location
    LSL Pharma Group Inc540, rue d'Avaugour, Office 1800BOUCHERVILLE J4B 0G6CanadaCAN
  • Phone+1 (450) 681-7744
  • Fax+1 (450) 681-8400
  • Websitehttps://www.groupelslpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.